Formulation | BEXSERO (Meningococcal Group B Vaccine) Info for HCPs

BEXSERO FORMULATION

BEXSERO is the only meningitis B (MenB) monovalent vaccine that combines 4 different components: fHbp, NadA, NHBA, and OMV, each of which targets a different mechanism involved in MenB survival and disease development.^1-3

More than 99% of invasive MenB strains contain genes for at least 1 BEXSERO component.¹

MenB strains can express varying amounts of surface protein^4,5
BEXSERO, with 4 distinct components, offers the potential to protect against invasive MenB strains, even when the expression of 1 component is low or antigenically different^4,5,*
The majority of invasive MenB strains contain genes for more than 1 BEXSERO component, potentially providing multiple targets for vaccine-induced antibodies^1,5

*The susceptibility of serogroup B meningococci to complement-mediated antibody-dependent killing following vaccination with BEXSERO is dependent on both the antigenic similarity of the bacterial and vaccine antigens, as well as the amount of antigen expressed on the surface of the invading meningococci.⁶

INDICATION & IMPORTANT SAFETY INFO

INDICATION

INDICATION

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

IMPORTANT SAFETY INFORMATION FOR BEXSERO

Do not administer BEXSERO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of BEXSERO or after a previous dose of BEXSERO

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

IMPORTANT SAFETY INFORMATION FOR BEXSERO

Do not administer BEXSERO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of BEXSERO or after a previous dose of BEXSERO

Do not administer BEXSERO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of BEXSERO or after a previous dose of BEXSERO
Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following the administration of BEXSERO
The tip cap of the prefilled syringe may or may not be made with natural rubber latex. Natural rubber latex may cause allergic reactions. Please check the carton
Syncope (fainting) can occur in association with administration of BEXSERO. Ensure procedures are in place to avoid injury from falling associated with syncope
BEXSERO may not protect all vaccine recipients and may not provide protection against all meningococcal serogroup B strains
Some individuals with altered immunocompetence may have reduced immune responses to BEXSERO
Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with BEXSERO
The most commonly reported (≥10%) solicited adverse reactions in a Phase 3 clinical trial were pain at the injection site (87%-92%), fatigue (45%-49%), headache (37%-41%), nausea (11%-13%), erythema (10%-15%), myalgia (10%-14%), and swelling (10%-14%)

Please see full Prescribing Information for BEXSERO.